Pancreatic Cancer Research

ResearcherUniversity of MissouriActive in the last 2 years

Kuirong Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9512-6463; OpenAlex author ID A5102894357. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 5 papers · 2026: 1 paper

Papers 19

  1. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRAS G12D-mutant pancreatic cancer: a phase 1b/2 trial. First author DOI 10.1038/s41591-026-04538-9↗
  2. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Last author DOI 10.1002/wjs.12630↗
  3. Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer. Co-author DOI 10.1007/s00423-025-03933-z↗
  4. Exploring the biological mechanism and clinical value of perineural invasion in pancreatic cancer. Last author DOI 10.1016/j.canlet.2025.217515↗
  5. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  6. Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Last author DOI 10.1186/s12885-025-14601-2↗
  7. High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance. Co-author DOI 10.1007/s10495-023-01901-w↗
  8. NOP10 predicts poor prognosis and promotes pancreatic cancer progression. Last author DOI 10.1186/s12885-024-13180-y↗
  9. Role of a novel circRNA-CGNL1 in regulating pancreatic cancer progression via NUDT4-HDAC4-RUNX2-GAMT-mediated apoptosis. Co-author DOI 10.1186/s12943-023-01923-7↗
  10. Analyzing the role of TM4SF1 expression in pancreatic adenocarcinoma: understanding prognostic implications and therapeutic opportunities. Last author DOI 10.21037/jgo-24-564↗
  11. Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. Co-author DOI 10.1002/cam4.5472↗
  12. Identification of FEZ2 as a potential oncogene in pancreatic ductal adenocarcinoma. Co-author DOI 10.7717/peerj.12736↗
  13. LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.3389/fcell.2021.647387↗
  14. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Last author DOI 10.1002/ijc.32827↗
  15. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Last author DOI 10.1016/j.canlet.2020.08.001↗
  16. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Co-author DOI 10.1002/ijc.31173↗
  17. Yin Yang-1 suppresses pancreatic ductal adenocarcinoma cell proliferation and tumor growth by regulating SOX2OT-SOX2 axis. Last author DOI 10.1016/j.canlet.2017.08.032↗
  18. Yin Yang-1 increases apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.8654↗
  19. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Co-author DOI 10.1016/j.canlet.2012.11.005↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zipeng Lu · 6 shared papers, 2018–2025 · strength 1.11
  2. Xumin Huang · 4 shared papers, 2020–2025 · strength 0.65
  3. Yi Miao · 6 shared papers, 2016–2023 · strength 0.59
  4. Yi Miao · 4 shared papers, 2013–2025 · strength 0.59
  5. Hao Yuan · 5 shared papers, 2018–2024 · strength 0.57
  6. Min Tu · 4 shared papers, 2013–2025 · strength 0.53
  7. Jishu Wei · 3 shared papers, 2013–2025 · strength 0.50
  8. Junli Wu · 3 shared papers, 2013–2025 · strength 0.50
  9. Pengfei Wu · 2 shared papers, 2025 · strength 0.45
  10. Baobao Cai · 3 shared papers, 2013–2025 · strength 0.45
  11. Wentao Gao · 3 shared papers, 2013–2025 · strength 0.43
  12. Qun Chen · 3 shared papers, 2020–2025 · strength 0.43
  13. Guangfu Wang · 2 shared papers, 2023–2024 · strength 0.41
  14. Yufeng Zhang · 2 shared papers, 2024–2025 · strength 0.41
  15. Kai Zhang · 2 shared papers, 2022–2025 · strength 0.38
  16. Guodong Shi · 4 shared papers, 2017–2020 · strength 0.34
  17. Yang Feng Wu · 2 shared papers, 2018–2025 · strength 0.32
  18. Jin Dou · 1 shared paper, 2024 · strength 0.31
  19. Xinjian Liu · 2 shared papers, 2021–2024 · strength 0.29
  20. Dong Xu · 1 shared paper, 2024 · strength 0.28
  21. Qianqian Wang · 1 shared paper, 2025 · strength 0.25
  22. Dong Xu · 1 shared paper, 2025 · strength 0.25
  23. Liwei Wang · 1 shared paper, 2026 · strength 0.24
  24. Jiujie Cui · 1 shared paper, 2026 · strength 0.24
  25. Jingjing Zhang · 3 shared papers, 2016–2020 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.